Catheterization and Cardiovascular Interventions
Volume 97, Issue 5 pp. 805-806
EDITORIAL COMMENT

New generation drug eluting stents: Closing the gap in sex disparity in cardiovascular outcomes in women

Odayme Quesada MD, 

Odayme Quesada MD

The Carl and Edyth Lindner Center for Research and Education, The Christ Hospital, Cincinnati, Ohio

Women's Heart Center, The Christ Hospital Heart, Vascular, and Lung Institute, Cincinnati, Ohio

Search for more papers by this author
Timothy D. Henry MD, 

Corresponding Author

Timothy D. Henry MD

The Carl and Edyth Lindner Center for Research and Education, The Christ Hospital, Cincinnati, Ohio

Correspondence

Timothy D. Henry, The Carl and Edyth Lindner Center for Research and Education, 2123 Auburn Avenue, Suite 424, Cincinnati, OH 45219.

Email: [email protected]

Search for more papers by this author
First published: 14 April 2021
https://doi.org/10.1002/ccd.29665
Expert Article Analysis for: Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration

Funding information: National Institutes of Health, Grant/Award Number: K23 HL151867

Key Points

  • Use of the novel COMBO stent, circumferentially coated with anti-CD34 antibodies to promote endothelialization and decrease inflammation led to extremely low 1-year event rates with no sex differences .
  • Technological advances in new generation drug-eluting stents has closed the gap in sex disparities for cardiovascular outcomes.
  • Women continue to be underrepresented in clinical trials and there is room to improve procedure related aspects such as radial access and potent antiplatelet therapy.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.